These agents exbibit nanomolar potency in BC cell lines and are designed to mimic estradiol activity by binding ER in the nucleus, promoting its translocation to extranuclear compartments, and ultimately disrupting proliferative signaling. Here, ESR1 is linked to breast cancer.